PT-141
Bremelanotide (PT-141)
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist developed from the tanning peptide Melanotan II, FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is widely used off-label by both men and women to enhance libido, sexual arousal, and erectile function through central nervous system pathways rather than vascular mechanisms.
Mechanism of Action
PT-141 acts as an agonist at melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system, activating dopaminergic pathways that modulate sexual motivation and arousal at the central level. Unlike PDE5 inhibitors (e.g., sildenafil), it does not primarily act on vascular smooth muscle but instead increases endogenous sexual desire signaling in the brain. This central mechanism makes it effective for both psychogenic and organic sexual dysfunction in men and women.
Evidence by Health Goal(10 goals)
Dosing Protocols
45-90 minutes before sexual activity
Cycle: Limit to 8 uses per month to minimize desensitization and side effects
Subcutaneous injection into abdomen or thigh is the most common route. Many users find 1mg sufficient with fewer side effects than 2mg. Start at the lower end of the dose range on first use.
60-90 minutes before sexual activity
Cycle: Limit to 8 uses per month
Nasal spray formulations have lower and more variable bioavailability (~15-20% vs ~80%+ for SC injection). Nausea is reported slightly less frequently with nasal route. FDA-approved Vyleesi uses subcutaneous auto-injector at 1.75mg.
Safety & Side Effects
PT-141 has an acceptable safety profile for as-needed use, but the transient hypertensive effect makes it contraindicated in individuals with uncontrolled hypertension or high cardiovascular risk; it is FDA-approved as Vyleesi but classified as a prescription medication, and off-label use via peptide vendors operates in a legal gray area in many jurisdictions.
Possible Side Effects
- !Nausea and vomiting (most common, affecting up to 40% of users, typically onset 30-60 min post-dose)
- !Facial flushing and skin warmth lasting 1-3 hours post-administration
- !Transient hyperpigmentation of face, gums, or breasts with repeated use
- !Transient blood pressure increase (up to 6-10 mmHg systolic) lasting approximately 12 hours
- !Headache, often associated with the blood pressure elevation
- !Fatigue and yawning, particularly in the hours following administration
- !Local injection site reactions including erythema, bruising, and induration
- !Spontaneous or prolonged erections (priapism risk in men at higher doses)
Interactions
- -Potentiates hypotensive effects of antihypertensive medications - blood pressure may drop excessively post-peak hypertensive phase
- -Additive hypotensive risk with PDE5 inhibitors (sildenafil, tadalafil) - concurrent use is not recommended and increases cardiovascular strain
- -May enhance dopaminergic tone - use with caution alongside dopamine agonists (e.g., cabergoline) or dopamine-affecting psychiatric medications
- -Alcohol consumption may worsen nausea and potentiate blood pressure variability when used concurrently
- -Concomitant use with other melanocortin-pathway peptides (e.g., Melanotan II) increases risk of hyperpigmentation and cardiovascular side effects
Cost & Where to Buy
Research-grade PT-141 from peptide vendors typically costs $30-80 per 10mg vial; assuming 4-8 uses per month at 1-2mg per use, monthly cost ranges accordingly. Prescription Vyleesi (1.75mg auto-injector) can exceed $900 per dose without insurance. Nasal spray compounded formulations cost approximately $60-120 per vial.
Search on Amazon